Bile Acids and Their Receptors

This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target. It covers all major areas of research in this field, from genetics, chemistry, in silico modeling, molecular biology to cli...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Fiorucci, Stefano (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Distrutti, Eleonora (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2019.
Έκδοση:1st ed. 2019.
Σειρά:Handbook of Experimental Pharmacology, 256
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04588nam a2200541 4500
001 978-3-030-22005-1
003 DE-He213
005 20191220125610.0
007 cr nn 008mamaa
008 190903s2019 gw | s |||| 0|eng d
020 |a 9783030220051  |9 978-3-030-22005-1 
024 7 |a 10.1007/978-3-030-22005-1  |2 doi 
040 |d GrThAP 
050 4 |a RM1-950 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
072 7 |a MKG  |2 thema 
082 0 4 |a 615  |2 23 
245 1 0 |a Bile Acids and Their Receptors  |h [electronic resource] /  |c edited by Stefano Fiorucci, Eleonora Distrutti. 
250 |a 1st ed. 2019. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2019. 
300 |a X, 378 p. 57 illus., 37 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Handbook of Experimental Pharmacology,  |x 0171-2004 ;  |v 256 
505 0 |a Preface -- Part 1. Bile acids as signaling molecules and their receptors -- 1. A short history of bile acid pharmacology -- 2. Bile acids activated receptors: a review of GPBAR1 (TGR5) and other G-protein-coupled receptors -- 3. Bile acid activated receptors: a review of FXR and other Nuclear receptors -- 4. The intestinal enterokine fibroblast growth factor 15/19 in bile acid metabolism -- 5. Signaling from intestine to the host. How bile acids regulate intestinal and liver immunity -- Part 2. General pharmacology of bile acid activated receptors and their ligands -- 6. Modeling of bile acid activated receptors as a tool for pharmacological development -- 7. Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists and antagonists -- 8. Non steroidal FXR ligands: current status and clinical applications -- 9. Intestinal selective FXR agonists and their potential in treating liver and metabolic diseases -- Part 3. Bile acids and their derivatives as drugs -- 10. UDCA, Nor-UDCA and T-UDCA: a review of their mechanisms of action and clinical applications -- 11. Chenodeoxycholic acid: an update on its therapeutic appplications and safety profile -- 12. Obeticholic acid: a review of its mechanisms of action and clinical applications -- Part 4. Bile acid activated receptors as therapeutic targets -- 13. Targeting FXR in cholestasis -- 14. FXR agonists for the treatment of NASH and other metabolic disorders -- 15. Targeting bile acids activated receptors in bariatric surgery. 
520 |a This book focusses on the latest results related to the field of bile acids as signaling molecules and describes how these receptors have become a major pharmacological target. It covers all major areas of research in this field, from genetics, chemistry, in silico modeling, molecular biology to clinical applications, offering a cross-country view of the functional role of bile acids as signaling molecules, virtually acting on all major areas of metabolism. While FXR and GPBAR1 are essential bile acid sensors that integrate the de novo bile acid synthesis with intestinal microbiota and liver metabolism, in a broader sense, BARs play a pathogenic role in the development of common human alignments including liver, intestinal and metabolic disorders, such as steatosis (NAFLD) and steato-hepatitis (NASH), diabetes, obesity and atherosclerosis. . 
650 0 |a Pharmacology. 
650 0 |a Gastroenterology . 
650 0 |a Hepatology. 
650 0 |a Endocrinology . 
650 1 4 |a Pharmacology/Toxicology.  |0 http://scigraph.springernature.com/things/product-market-codes/B21007 
650 2 4 |a Gastroenterology.  |0 http://scigraph.springernature.com/things/product-market-codes/H33061 
650 2 4 |a Hepatology.  |0 http://scigraph.springernature.com/things/product-market-codes/H33088 
650 2 4 |a Endocrinology.  |0 http://scigraph.springernature.com/things/product-market-codes/H33053 
700 1 |a Fiorucci, Stefano.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Distrutti, Eleonora.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783030220044 
776 0 8 |i Printed edition:  |z 9783030220068 
776 0 8 |i Printed edition:  |z 9783030220075 
830 0 |a Handbook of Experimental Pharmacology,  |x 0171-2004 ;  |v 256 
856 4 0 |u https://doi.org/10.1007/978-3-030-22005-1  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)